针对ARPC1B+癌症干细胞,使胰腺癌对吉姆西塔治疗产生敏感性
Yang Wu1, Jianpeng Zhang2, Weixiong Zhu3
1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Cell proliferation
|September 3, 2025
概括
胰腺癌干细胞 (CSCs) 可以被CK-636向. 结合吉姆西塔和CK-636的联合治疗显示出优异的抗瘤作用,克服了药物耐药性.
科学领域:
- 癌症学
- 癌症生物学
- 药物发现
背景情况:
- 胰腺癌含有表达ARPC1B的耐凝癌干细胞 (CSCs).
- 开发克服耐药性的策略对于改善患者的治疗结果至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K